ERBB2 and cancer: To this end, alternative anti-HER2 antibody-based therapeutics including antibody-drug conjugates, such as T-DM1 and DS8201s, and bispecific antibodies (BsAbs) are being actively developed and have shown significant clinical benefits in several cancer indications [9–12].